Olanzapine in the Treatment of Patients With Anorexia Nervosa
Information source: Ottawa Health Research Institute
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anorexia Nervosa
Intervention: Olanzapine (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Ottawa Health Research Institute Official(s) and/or principal investigator(s):
H Bissada, Principal Investigator, Affiliation: OHRI
Overall contact:
H Bissada, Phone: 613-737-8042
Summary
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication,
Olanzapine, in achieving desired weight gain in patients identified as having Anorexia
Nervosa, either restricting or binge/purge subtype. The study will also evaluate the
possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or
anxiety symptoms associated with this disorder.
Clinical Details
Official title: Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: The primary outcome of this study is to evaluate the Olanzapine weight gain effect, when administered to Anorexia Nervosa patients in order to facilitate the desired weight component of their nutritional rehabilitation.
Secondary outcome: The secondary outcome it the anti-obsessional and anti-anxiety properties to Olanzapine which could prove beneficial to Anorexia Nervosa patients.
Detailed description:
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication,
Olanzapine, in achieving desired weight gain in patients identified as having Anorexia
Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible
beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety
symptoms associated with this disorder.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- those who meet DSM IV criteria of Anorexia Nervosa- either restricting or binge/purge
subtype
Exclusion Criteria:
- patients who are actively self destructive and/or suicidal
- patients whose medical status is seriously compromised
- patients whose eating disorder is superimposed on a major psychiatric disorder such as
schizophrenia, major affective disorders, dissociative disorder or an active substance
abuse disorder.
Locations and Contacts
H Bissada, Phone: 613-737-8042
Ottawa Hospital, Ottawa, Ontario K1Y 4E9, Canada; Recruiting
Additional Information
Starting date: September 2000
Ending date: September 2007
Last updated: July 25, 2007
|
